Biocompatible Glue‐Enabled Drug Localization and Mechanical Reinforcement of Lyophilized Microneedle Systems

Why It Matters

LMS‑BG removes key barriers to clinical adoption of dissolving microneedles by delivering rapid, precise dosing while maintaining insertion strength, opening new markets for needle‑free therapeutics.

Key Takeaways

• 11× faster dissolution than conventional DMNs
• 96% drug retained in microneedle tip
• 90% delivery within 2 minutes
• Biodegradable glue reinforces mechanical strength
• Scalable across polymer, hydrogel, PLGA platforms

Pulse Analysis

Dissolving microneedle arrays have long promised painless, needle‑free drug administration, yet commercial adoption remains limited. Traditional fabrication traps a portion of the active ingredient in the backing layer, reducing dose accuracy and requiring prolonged skin residence for complete dissolution. Lyophilization emerged as a fix, creating a porous, amorphous tip that absorbs interstitial fluid rapidly, but the resulting structure is mechanically fragile, often buckling during insertion. These shortcomings—drug loss, slow release, and weak insertion force—continue to hinder regulatory approval and patient compliance.

The LMS‑BG platform addresses those gaps by coupling a lyophilized, drug‑laden tip to a pre‑formed backing with an ethanol‑based, biodegradable glue. The glue partially infiltrates the porous tip, locking the active compound in place while simultaneously reinforcing the needle shaft, yielding an 11‑fold acceleration in dissolution and preserving over 96 % of the payload in the tip. In rat models, lidocaine delivery surpassed 90 % of the intended dose within two minutes, producing faster onset of anesthesia than standard lidocaine gel and demonstrating excellent biocompatibility. Moreover, the method translates to diverse microneedle architectures, including soluble polymers, hydrogel matrices, and PLGA nanoparticle composites, confirming its manufacturing versatility.

By solving the twin challenges of mechanical robustness and rapid drug release, LMS‑BG could accelerate the path to market for a new generation of transdermal therapeutics, from local anesthetics to vaccines and biologics. The glue‑based assembly is compatible with existing roll‑to‑roll production lines, reducing capital expenditures and enabling high‑volume scaling without compromising sterility. Regulatory bodies are likely to view the biodegradable glue as a safe excipient, simplifying approval pathways. As patients and clinicians demand faster, more reliable needle‑free options, platforms that combine speed, precision, and manufacturability—such as LMS‑BG—are poised to reshape the pharmaceutical delivery landscape.